Ultimaster™ Family Clinical Program
2
neutrals-100
true
References
References
A comprehensive clinical program
3
A remarkable 16 CE marked indications
3
youtube
XzDf-I4c-Cw
Consistent good safety* data at 1 year from controlled clinical trial <sup>4</sup> and routine clinical practice<sup>8</sup>
3
neutrals-100
Sustained long-term safety* from controlled clinical trial4
3
1-month DAPT for HBR patients
3
MASTER DAPT is the largest multi-center randomized controlled study to confirm the safety and efficacy of abbreviated DAP in HBR patients following stenting procedures with Ultimaster Family DES.
Learn more
Learn more
tisSecondary
References
text
Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105;
text
Barbato E et al. EuroIntervention 2015;11:541–8;
text
Saito S et al. Eur Heart J 2014;35:2021–31;
text
Wijns W et al. EuroIntervention 2018;14:e343–51;
text
Valdes-Chavarri M et al. EuroIntervention 2019;14:e1836-42;
text
Chevalier B et al. Circ Cardiovasc Interv 2017;10e004801;
text
Mohamed et al. EuroIntervention 2020;16:603-612
text
Cimci M et al. Heart 2022;108:1310-1318.
text
Frigoli E et al. Am Heart J 2019;209:97-105
text
Valgimigli M et al. N Engl J Med 2021;385:1643-1655
text
Kozuma K et al. Circ J 2020;85:19-26
text
Hioki H et al.J Cardiol 2021;78:107-113
Featured products
3
default-carousel
Ultimaster™ Tansei™
Sirolimus Eluting Coronary Stent System
default-carousel
Ultimaster™ Nagomi™
Sirolimus Eluting Coronary Stent System